251 related articles for article (PubMed ID: 31640781)
1. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
2. Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.
Zhao S; Geybels MS; Leonardson A; Rubicz R; Kolb S; Yan Q; Klotzle B; Bibikova M; Hurtado-Coll A; Troyer D; Lance R; Lin DW; Wright JL; Ostrander EA; Fan JB; Feng Z; Stanford JL
Clin Cancer Res; 2017 Jan; 23(1):311-319. PubMed ID: 27358489
[TBL] [Abstract][Full Text] [Related]
3. Epigenome-wide DNA methylation profiling of periprostatic adipose tissue in prostate cancer patients with excess adiposity-a pilot study.
Cheng Y; Monteiro C; Matos A; You J; Fraga A; Pereira C; Catalán V; Rodríguez A; Gómez-Ambrosi J; Frühbeck G; Ribeiro R; Hu P
Clin Epigenetics; 2018; 10():54. PubMed ID: 29692867
[TBL] [Abstract][Full Text] [Related]
4. Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors.
Li QK; Chen J; Hu Y; Höti N; Lih TM; Thomas SN; Chen L; Roy S; Meeker A; Shah P; Chen L; Bova GS; Zhang B; Zhang H
Sci Rep; 2021 Sep; 11(1):18936. PubMed ID: 34556748
[TBL] [Abstract][Full Text] [Related]
5. Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1.
Spans L; Van den Broeck T; Smeets E; Prekovic S; Thienpont B; Lambrechts D; Karnes RJ; Erho N; Alshalalfa M; Davicioni E; Helsen C; Gevaert T; Tosco L; Haustermans K; Lerut E; Joniau S; Claessens F
Oncotarget; 2016 Apr; 7(17):24326-38. PubMed ID: 27014907
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data.
Dunn TA; Fedor HL; De Marzo AM; Luo J
Asian J Androl; 2012 May; 14(3):385-92. PubMed ID: 22306912
[TBL] [Abstract][Full Text] [Related]
7. Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer.
Schulz WA; Alexa A; Jung V; Hader C; Hoffmann MJ; Yamanaka M; Fritzsche S; Wlazlinski A; Müller M; Lengauer T; Engers R; Florl AR; Wullich B; Rahnenführer J
Mol Cancer; 2007 Feb; 6():14. PubMed ID: 17280610
[TBL] [Abstract][Full Text] [Related]
8. Decreased Expression of MYPT1 Contributes to Tumor Angiogenesis and Poor Patient Prognosis in Human Prostate Cancer.
Liang Y; Zhuo Y; Lin Z; Jiang F; Dai Q; Lu J; Dong W; Zhu X; Han Z; Zhong W
Curr Mol Med; 2018; 18(2):100-108. PubMed ID: 29974831
[TBL] [Abstract][Full Text] [Related]
9. Alternations of gene expression in PI3K and AR pathways and DNA methylation features contribute to metastasis of prostate cancer.
Zhao Y; Hu X; Yu H; Liu X; Sun H; Shao C
Cell Mol Life Sci; 2022 Jul; 79(8):436. PubMed ID: 35864178
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study.
Wang Q; Ye Y; Yu H; Lin SH; Tu H; Liang D; Chang DW; Huang M; Wu X
Cancer Immunol Immunother; 2021 Mar; 70(3):701-712. PubMed ID: 32909077
[TBL] [Abstract][Full Text] [Related]
11. A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors.
Ahmad AS; Vasiljević N; Carter P; Berney DM; Møller H; Foster CS; Cuzick J; Lorincz AT
Oncotarget; 2016 Nov; 7(44):71833-71840. PubMed ID: 27708246
[TBL] [Abstract][Full Text] [Related]
12. A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients.
Ebrahimizadeh W; Guérard KP; Rouzbeh S; Scarlata E; Brimo F; Patel PG; Jamaspishvili T; Hamel L; Aprikian AG; Lee AY; Berman DM; Bartlett JMS; Chevalier S; Lapointe J
Br J Cancer; 2023 Jun; 128(12):2165-2174. PubMed ID: 37037938
[TBL] [Abstract][Full Text] [Related]
13. Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness.
Liu Y; Chen J; Sethi A; Li QK; Chen L; Collins B; Gillet LC; Wollscheid B; Zhang H; Aebersold R
Mol Cell Proteomics; 2014 Jul; 13(7):1753-68. PubMed ID: 24741114
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease.
Charlton PV; O'Reilly D; Philippou Y; Rao SR; Lamb ADG; Mills IG; Higgins GS; Hamdy FC; Verrill C; Buffa FM; Bryant RJ
Prostate; 2024 Jul; 84(10):977-990. PubMed ID: 38654435
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide DNA methylation profiling is able to identify prefibrotic PMF cases at risk for progression to myelofibrosis.
Lehmann U; Stark H; Bartels S; Schlue J; Büsche G; Kreipe H
Clin Epigenetics; 2021 Feb; 13(1):28. PubMed ID: 33541399
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of alternative splicing across multiple transcriptomic cohorts reveals prognostic signatures in prostate cancer.
Mou Z; Spencer J; McGrath JS; Harries LW
Hum Genomics; 2023 Nov; 17(1):97. PubMed ID: 37924098
[TBL] [Abstract][Full Text] [Related]
17. Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing.
Ma X; Guo J; Liu K; Chen L; Liu D; Dong S; Xia J; Long Q; Yue Y; Zhao P; Hu F; Xiao Z; Pan X; Xiao K; Cheng Z; Ke Z; Chen ZS; Zou C
Mol Cancer; 2020 Oct; 19(1):147. PubMed ID: 33032611
[TBL] [Abstract][Full Text] [Related]
18. [Bioinformatics-based analysis of the effect of general Transcription Factor IIH on prognosis of Prostate cancer].
Li JC; Zhu XJ; Ye JH; Tan ZH; Cai SH; Deng YL; Chen J; Tian WC; Luo DH; Zhong WD
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1410-1417. PubMed ID: 38644292
[No Abstract] [Full Text] [Related]
19. DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival.
Fleischer T; Klajic J; Aure MR; Louhimo R; Pladsen AV; Ottestad L; Touleimat N; Laakso M; Halvorsen AR; Grenaker Alnæs GI; Riis ML; Helland Å; Hautaniemi S; Lønning PE; Naume B; Børresen-Dale AL; Tost J; Kristensen VN
Oncotarget; 2017 Jan; 8(1):1074-1082. PubMed ID: 27911866
[TBL] [Abstract][Full Text] [Related]
20. Proteomic-based stratification of intermediate-risk prostate cancer patients.
Zhong Q; Sun R; Aref AT; Noor Z; Anees A; Zhu Y; Lucas N; Poulos RC; Lyu M; Zhu T; Chen GB; Wang Y; Ding X; Rutishauser D; Rupp NJ; Rueschoff JH; Poyet C; Hermanns T; Fankhauser C; Rodríguez Martínez M; Shao W; Buljan M; Neumann JF; Beyer A; Hains PG; Reddel RR; Robinson PJ; Aebersold R; Guo T; Wild PJ
Life Sci Alliance; 2024 Feb; 7(2):. PubMed ID: 38052461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
